In a groundbreaking development, the Centers for Medicare & Medicaid Services (CMS) has announced the implementation of a program that will cover up to $500 worth of hemp-derived products for eligible Medicare patients. This initiative, which is set to launch on April 1, 2026, has garnered attention from various stakeholders, including notable figures like Mehmet Oz, who have long advocated for broader access to cannabis-derived therapies.
The program primarily focuses on cannabidiol (CBD) products but also permits a limited amount of tetrahydrocannabinol (THC), specifically allowing a maximum delta-9 THC percentage of 0.3 by dry weight and a total THC limit of 3 milligrams per serving. This nuanced approach aims to balance the therapeutic benefits of hemp-derived products while addressing regulatory concerns.
In the backdrop of this initiative, the government has filed a brief asserting that anti-cannabis organizations, including Smart Approaches to Marijuana (SAM), do not have standing to challenge the Medicare hemp coverage policy. Individual plaintiff David Evans, a Medicare recipient, claims he has standing but has been rejected by federal agencies. The government argues that the plaintiffs have not suffered harm from the Medicare hemp program, which is designed as a voluntary component of existing models, allowing providers to consult with beneficiaries about eligible hemp products.
Judge Trevor N. McFadden recently rejected the plaintiffs’ request for a temporary restraining order to halt the program’s launch, indicating a judicial endorsement of the government’s position. This ruling is significant as it underscores the legal framework supporting the Medicare hemp coverage initiative, which has been finalized to allow coverage of certain hemp products as specialized, non-primarily health-related benefits through Medicare Advantage plans.
While the program is poised to enhance access to hemp-derived products, it is important to note that CMS does not pay for these products under the Beneficiary Engagement Incentive (BEI). Instead, providers will furnish eligible products at their own cost, operating within a shared-savings framework that defines the underlying models. This structure raises questions about the financial implications for both providers and beneficiaries.
The White House Office of Management and Budget has also been involved, holding meetings regarding a Food and Drug Administration (FDA) enforcement policy on CBD products. The FDA has issued guidance indicating it does not intend to interfere with the Medicare hemp-derived products coverage plan, which could pave the way for a more favorable regulatory environment for CBD in the healthcare sector.
As the program approaches its launch date, reactions from various stakeholders have begun to surface. The government brief highlights that Evans, who opposes hemp products, will not utilize them himself, suggesting a disconnect between the advocacy efforts of organizations like SAM and the actual needs of Medicare beneficiaries. The brief also emphasizes that the resources spent by these organizations to oppose the program align with their missions rather than detract from them.
In summary, the Medicare hemp coverage program represents a significant shift in healthcare policy, potentially improving access to CBD products for eligible patients. With figures like Mehmet Oz advocating for this initiative, the implications for patient care and the broader cannabis industry are profound. As the program unfolds, it will be essential to monitor its impact on both healthcare access and the evolving landscape of cannabis regulation.
